Schön H J, Czerwenka K F, Manavi M, Schatten C, Knogler W, Kubista E
Institute of Medical Chemistry, University of Vienna.
Wien Klin Wochenschr. 1990 Aug 3;102(15):449-54.
In this study, the diagnostic accuracy and practicability of different hybridization techniques for the detection of human papilloma virus (HPV) DNA were tested. Cervical cell scrapes (n = 67) were analysed for HPV-DNAs 6/11 and 16, in order to compare a commercially available in situ DNA hybridization-assay with the conventional Southern-blot analysis. The in situ DNA hybridization-assay gave a sensitivity of 81.5%, a specificity of 97.5% and a diagnostic efficiency of 91.0% for HPV-DNAs 6/11. Using the same assay, we observed a sensitivity of 100%, a specificity of 96.3% and a diagnostic efficiency of 97.0% for HPV-DNA 16. The practicability of dot-blot DNA hybridization technique was tested on 176 cervical cell scrapes, in order to determine the prevalence rate of HPV-genotypes 6/11, 16/18 and 31/33/35. In the random control group (n = 106), 1.9% of the cases were HPV-DNA positive. In the cancer prevention group (n = 70), patients with reactive and reparative cell changes showed a HPV-DNA positivity of 55.0%, with mild (slight) dysplasia/CIN 1 of 73.7%, and with moderate to severe dysplasia/CIN 2 to CIN 3, including the carcinoma in situ/CIN 3 of 80.0%. Patients with squamous cell carcinoma of the cervix uteri gave HPV-DNA positive results in 96.2% of the cases. The suitability of in situ DNA hybridization for morphological studies was tested on tissue biopsies (n = 68). The HPV-DNAs 6/11 were found predominantly to 72.7% of the examined condylomas. The HPV-DNA positive cervices increased with the severity of the cytological dysplasia.(ABSTRACT TRUNCATED AT 250 WORDS)
在本研究中，测试了不同杂交技术检测人乳头瘤病毒（HPV）DNA的诊断准确性和实用性。分析了67份宫颈细胞刮片样本中的HPV-DNAs 6/11和16，以便将一种市售的原位DNA杂交检测法与传统的Southern印迹分析法进行比较。原位DNA杂交检测法对HPV-DNAs 6/11的灵敏度为81.5%，特异性为97.5%，诊断效率为91.0%。使用相同检测法，我们观察到对HPV-DNA 16的灵敏度为100%，特异性为96.3%，诊断效率为97.0%。对176份宫颈细胞刮片样本测试了斑点印迹DNA杂交技术的实用性，以确定HPV基因型6/11、16/18和31/33/35的流行率。在随机对照组（n = 106）中，1.9%的病例HPV-DNA呈阳性。在癌症预防组（n = 70）中，有反应性和修复性细胞改变的患者HPV-DNA阳性率为55.0%，轻度（轻微）发育异常/CIN 1为73.7%，中度至重度发育异常/CIN 2至CIN 3（包括原位癌/CIN 3）为80.0%。子宫颈鳞状细胞癌患者96.2%的病例HPV-DNA检测结果为阳性。对68份组织活检样本测试了原位DNA杂交用于形态学研究的适用性。在所检查的尖锐湿疣中，72.7%主要检测到HPV-DNAs 6/11。HPV-DNA阳性的宫颈随着细胞学发育异常的严重程度增加而增多。（摘要截选至250词）
